2,691
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Roche's recently active trials. Comparator arms are excluded.
- Inavolisib12 trials
- Atezolizumab12 trials
- Divarasib8 trials
- Fulvestrant8 trials
- Tocilizumab8 trials
- Palbociclib7 trials
Upcoming readouts
Next primary completion dates among Roche's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Nov 2026NAUTIKA1: A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III N…Phase 2
- Jan 2027Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B…Phase 2
- Apr 2027WILL-EMI: A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebra…Phase 3
- Jun 2027FENerations1: A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in…Phase 2
- Aug 2027GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With …Phase 3
- Sept 2027ZEBRHA 1: A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Partic…Phase 3
Top therapeutic areas
Conditions studied most often across Roche's recently active trials.
- Breast Cancer9 trials
- Non-Small Cell Lung Cancer4 trials
- Multiple Sclerosis4 trials
- Hemophilia A4 trials
- Obesity or Overweight3 trials
- Non-small Cell Lung Cancer3 trials
Roche pipeline by phase
The main study drugs across 231 active trials Roche leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 333 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Atezolizumab | 14 | 1 | Oct 2026 est. | NCT05904886 · NCT05112965 · NCT05091567 |
| AfimkibartRO7790121 | 13 | 9 | Sept 2026 est. | NCT07298421 · NCT07158242 · NCT06819891 |
| Inavolisib | 13 | 9 | Nov 2026 est. | NCT06790693 · NCT05894239 · NCT05646862 |
| Obinutuzumab | 9 | 4 | Jan 2027 est. | NCT06084936 · NCT05627557 · NCT04963296 |
| Cevostamab | 8 | 5 | Nov 2026 est. | NCT07555938 · NCT07629583 · NCT06934044 |
| GiredestrantGDC-9545 | 8 | 2 | Jul 2027 est. | NCT07541079 · NCT06065748 · NCT05306340 |
| Crovalimab | 5 | — | Apr 2027 est. | NCT04958265 · NCT04861259 · NCT04654468 |
| DivarasibGDC-6036 | 5 | 3 | Dec 2027 est. | NCT07541170 · NCT06793215 · NCT06497556 |
| Fenebrutinib | 5 | 1 | Jun 2027 est. | NCT04586023 · NCT04586010 · NCT04544449 |
| Glofitamab | 5 | 1 | Oct 2026 est. | NCT06047080 · NCT04980222 · NCT06624085 |
| Alectinib | 4 | 1 | Nov 2026 est. | NCT05170204 · NCT04302025 · NCT03178552 |
| Enicepatide | 4 | 4 | May 2027 est. | NCT07670416 · NCT07351058 · NCT07351045 |
| Entrectinib | 4 | — | Sept 2026 est. | NCT04603807 · NCT04589845 · NCT02568267 |
| Mosunetuzumab | 4 | 2 | Feb 2028 est. | NCT05171647 · NCT04712097 · NCT07598396 |
| Satralizumab | 4 | 1 | Nov 2026 est. | NCT05503264 · NCT05271409 · NCT05199688 |
| TrontinemabRO7126209 | 4 | 3 | Jul 2027 est. | NCT07717411 · NCT07170150 · NCT07169578 |
| NXT007 | 3 | 3 | Sept 2027 est. | NCT07416604 · NCT07416526 · NCT05987449 |
| Astegolimab | 2 | — | Jun 2027 est. | NCT05878769 · NCT05595642 |
| Ipatasertib | 2 | 1 | Feb 2028 est. | NCT05862285 · NCT04931342 |
| Ocrelizumab Co-formulated With rHuPH20 | 2 | — | Feb 2028 est. | NCT07503340 · NCT07667322 |
| Prasinezumab | 2 | 1 | Jun 2029 est. | NCT07174310 · NCT04777331 |
| Ranibizumab | 2 | 1 | Feb 2027 est. | NCT06847542 · NCT04657289 |
| Voretigene Neparvovec-rzyl | 2 | — | Oct 2027 est. | NCT00999609 · NCT01208389 |
| Alectnib | 1 | — | — | NCT03456076 |
| Baloxavir Marboxil | 1 | 1 | May 2027 est. | NCT06094010 |
| No Intervention | 1 | 1 | Jul 2035 est. | NCT07177352 |
| PDS Implant Pre-Filled with 100 mg/mL Ranibizumab | 1 | — | Jul 2027 est. | NCT04108156 |
| PDS Implant with Ranibizumab 100 mg/mL | 1 | 1 | Dec 2029 est. | NCT03683251 |
| Pertuzumab | 1 | — | Dec 2026 est. | NCT02320435 |
| Phesgo | 1 | — | Oct 2027 est. | NCT05296798 |
| Ranibizumab (10 mg/mL) | 1 | — | Jun 2027 est. | NCT05562947 |
| Sefaxersen (RO7434656) | 1 | — | — | NCT05797610 |
| Tiragolumab | 1 | — | — | NCT04665856 |
Phase 219 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| RO7204239 | 4 | — | Oct 2026 est. | NCT06965413 · NCT05548556 · NCT05115110 |
| RO7795081 | 4 | 1 | Nov 2026 est. | NCT07112872 · NCT07741604 · NCT07499050 |
| TobemstomigRO7247669 | 4 | — | Oct 2026 est. | NCT05852691 · NCT05805501 · NCT05645692 |
| Autogene cevumeran | 2 | — | Nov 2027 est. | NCT06534983 · NCT05968326 |
| OpRegen | 2 | 1 | Mar 2031 est. | NCT05626114 · NCT02286089 |
| RO7568282 | 2 | — | Dec 2028 est. | NCT07781657 · NCT07781644 |
| RO7771950 | 2 | 1 | Aug 2027 est. | NCT07413939 · NCT05593094 |
| delandistrogene moxeparvovec | 1 | — | — | NCT06128564 |
| DONQ52 | 1 | 1 | Jun 2027 est. | NCT07239336 |
| Mosunetuzumab (Cohorts A-C) | 1 | — | Jul 2027 est. | NCT05207670 |
| Ocrelizumab Test Formulation | 1 | — | — | NCT07074886 |
| Petrelintide | 1 | — | Nov 2027 est. | NCT07589686 |
| RO7046015 | 1 | — | — | NCT03100149 |
| RO7268489 | 1 | 1 | May 2028 est. | NCT07282574 |
| RO7269162 | 1 | — | Nov 2026 est. | NCT06402838 |
| RO7837195 | 1 | 1 | Aug 2027 est. | NCT06979336 |
| Selnoflast | 1 | 1 | Jan 2028 est. | NCT07448038 |
| Tominersen | 1 | — | — | NCT05686551 |
| Venetoclax | 1 | — | Oct 2026 est. | NCT06524375 |
Phase 139 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Mosunetuzumab (IV) | 2 | — | Sept 2030 est. | NCT04246086 · NCT03671018 |
| RAY121 | 2 | 1 | Mar 2027 est. | NCT06723106 · NCT06371417 |
| ALPS12 | 1 | 1 | Sept 2028 est. | NCT07107490 |
| AQUA07 | 1 | 1 | Aug 2030 est. | NCT07617337 |
| AUBE00 | 1 | 1 | Dec 2029 est. | NCT07030959 |
| Belvarafenib | 1 | — | Dec 2026 est. | NCT04835805 |
| Englumafusp alfa | 1 | — | Mar 2027 est. | NCT04077723 |
| Enzelkitug | 1 | — | Jul 2028 est. | NCT05581004 |
| ERY974 | 1 | — | — | NCT05022927 |
| GDC-1261 | 1 | 1 | Nov 2027 est. | NCT07567846 |
| GDC-4198 | 1 | 1 | Aug 2028 est. | NCT07100106 |
| GDC-6988 | 1 | 1 | Nov 2027 est. | NCT06603246 |
| P-CD19CD20-ALLO1 Cells | 1 | — | Aug 2032 est. | NCT07008378 |
| Phase I Arm A | 1 | 1 | May 2028 est. | NCT06619587 |
| RG6496 | 1 | — | Dec 2026 est. | NCT07246941 |
| RO7121932 IV | 1 | — | Jul 2027 est. | NCT05704361 |
| RO7497372 | 1 | — | Nov 2026 est. | NCT06847854 |
| RO7507062 | 1 | — | Nov 2027 est. | NCT05835986 |
| RO7566802 | 1 | — | Mar 2027 est. | NCT06031441 |
| RO7567132 and Atezolizumab | 1 | — | May 2027 est. | NCT06537310 |
| RO7656594 | 1 | 1 | Jun 2027 est. | NCT05800665 |
| RO7663498 | 1 | 1 | Jan 2028 est. | NCT07588100 |
| RO7673396 | 1 | 1 | Aug 2028 est. | NCT06884618 |
| RO7763505 | 1 | — | Oct 2026 est. | NCT07495813 |
| RO7806881 | 1 | 1 | Mar 2027 est. | NCT07271693 |
| RO7812653 | 1 | — | Mar 2027 est. | NCT07234942 |
| RO7823653 | 1 | 1 | Nov 2028 est. | NCT07425522 |
| RO7845860 | 1 | — | Feb 2031 est. | NCT07749157 |
| RO7851624 | 1 | 1 | Jul 2030 est. | NCT07558915 |
| RO7875913 | 1 | — | Jun 2030 est. | NCT07342114 |
| RO7890597 | 1 | 1 | Jun 2027 est. | NCT07797478 |
| ROSE12 | 1 | 1 | Oct 2027 est. | NCT05907980 |
| Runimotamab | 1 | — | Apr 2027 est. | NCT03448042 |
| SC Mosunetuzumab | 1 | — | Aug 2029 est. | NCT05169515 |
| SPK-10001 | 1 | 1 | Jan 2035 est. | NCT06826612 |
| SPK-3006 | 1 | — | Apr 2032 est. | NCT04093349 |
| SPK-8011QQ | 1 | 1 | Apr 2032 est. | NCT07226206 |
| SPLIT Abs | 1 | 1 | Feb 2034 est. | NCT07416552 |
| Vixarelimab | 1 | — | — | NCT06693908 |
Phase 47 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Ocrelizumab | 9 | 1 | Oct 2026 est. | NCT07483450 · NCT06675955 · NCT05269004 |
| Risdiplam | 4 | 2 | Oct 2026 est. | NCT05861999 · NCT05861986 · NCT05232929 |
| Emicizumab | 3 | 1 | Apr 2027 est. | NCT05181618 · NCT06998524 · NCT04431726 |
| Faricimab | 2 | — | Oct 2026 est. | NCT06795048 · NCT05224102 |
| LUCENTIS (Ranibizumab Injection) | 1 | 1 | Jul 2027 est. | NCT04853251 |
| OCR SC | 1 | 1 | Feb 2029 est. | NCT07609719 |
| Tumor Tissue and Blood Draw | 1 | 1 | Dec 2027 est. | NCT06274515 |
Combination backbones Capecitabine (1 trial), Docetaxel (1 trial). Established agents these trials combine with, listed separately from the drugs under study.
Derived from 231 active trials Roche leads; 231 name an intervention, folding into 98 phased drugs. 1 intervention carries no registry phase (observational studies, tests and devices) and is not shown. This is ComplyRx's reading of the registry, not Roche's own pipeline disclosure.
Roche trials
The 50 most significant of Roche's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| WeSMALong-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)NCT05232929Risdiplam | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 403 est. | 2 Oct 2026 |
| A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerNCT05852691Tobemstomig | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 83 est. | 19 Oct 2026 |
| MANATEEA Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyNCT05115110RO7204239 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 97 est. | 28 Oct 2026 |
| A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart DiseaseNCT07495813RO7763505 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 196 est. | 30 Oct 2026 |
| SHIELD DMDA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)NCT06450639Satralizumab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | 18 Nov 2026 |
| NAUTIKA1A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)NCT04302025Alectinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 99 est. | 30 Nov 2026 |
| A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsNCT06982131RO7795081 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 40 est. | 7 Dec 2026 |
| TAHOEAfimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's DiseaseNCT05910528Afimkibart | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 21 est. | 31 Dec 2026 |
| To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerNCT03006172Inavolisib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 200 est. | 31 Dec 2026 |
| Ametrine-1A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisNCT06589986Afimkibart | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 400 est. | 30 Jan 2027 |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLNCT06806033Obinutuzumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 130 est. | 31 Jan 2027 |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT06624085Glofitamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | 22 Mar 2027 |
| A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121Atezolizumab | — | Not yet scored | OngoingRecruiting | 700 est. | 31 Mar 2027 |
| AstefaniaA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyNCT04873362Atezolizumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,188 est. | 31 Mar 2027 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)NCT07234942RO7812653 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 6 est. | 31 Mar 2027 |
| WILL-EMIA Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseNCT06998524Emicizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 75 est. | 30 Apr 2027 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515Enicepatide | Phase 1 | Not yet scored | OngoingRecruiting | 36 est. | 14 May 2027 |
| FENerations1A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)NCT07161258Fenebrutinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 12 est. | 8 Jun 2027 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerNCT05800665RO7656594 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 210 est. | 30 Jun 2027 |
| Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsNCT04140500RO7247669 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 170 est. | 30 Jun 2027 |
| HONUAn Observational Study of the Progression of Intermediate Age-Related Macular DegenerationNCT05300724 | — | Not yet scored | OngoingActive, not recruiting | 400 est. | 30 Jun 2027 |
| A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisNCT05704361RO7121932 IV | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 119 est. | 8 Jul 2027 |
| Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseaseNCT04639050RO7126209 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 241 est. | 31 Jul 2027 |
| GLOBRYTEA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaNCT06084936Obinutuzumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 182 est. | 31 Aug 2027 |
| ZEBRHA 1A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ANCT07416526NXT007 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 126 est. | 23 Sept 2027 |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaNCT06047080Glofitamab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,130 est. | 1 Oct 2027 |
| ZYNERGYA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686Petrelintide | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 486 est. | 12 Nov 2027 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerNCT07567846GDC-1261 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 260 est. | 30 Nov 2027 |
| REMERGEA Study to Investigate Mechanisms of Resistance to Breast Cancer TherapiesNCT06274515Tumor Tissue and Blood Draw | Phase 4 | Locked · track to reveal | OngoingRecruiting | 320 est. | 31 Dec 2027 |
| CENOTEA Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic RetinopathyNCT07588100RO7663498 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | 20 Jan 2028 |
| RIVULETA Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac EventsNCT07448038Selnoflast | Phase 2 | Locked · track to reveal | OngoingRecruiting | 162 est. | 31 Jan 2028 |
| A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney FunctionsNCT07741604RO7795081 | Phase 1 | Not yet scored | OngoingRecruiting | 60 est. | 1 Feb 2028 |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416Enicepatide | Phase 3 | Not yet scored | OngoingRecruiting | 300 est. | 24 Feb 2028 |
| BOUQUETA Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsNCT04931342Ipatasertib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 176 est. | 28 Feb 2028 |
| ZEBRHA 2A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ANCT07416604NXT007 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 360 est. | 29 Feb 2028 |
| HINALEA 2A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyNCT05861999Risdiplam | Phase 4 | Locked · track to reveal | OngoingRecruiting | 28 est. | 31 Mar 2028 |
| HINALEA 1A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyNCT05861986Risdiplam | Phase 4 | Locked · track to reveal | OngoingRecruiting | 28 est. | 31 Mar 2028 |
| InavoPCA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150Inavolisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 100 est. | 31 Mar 2028 |
| SurfSubQA Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150Ocrelizumab | — | Not yet scored | OngoingRecruiting | 842 est. | 31 Mar 2028 |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748Giredestrant | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,050 est. | 20 Apr 2028 |
| Enith1A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045Enicepatide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 24 Jul 2028 |
| PLYCOMA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaNCT05583617Cevostamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 200 est. | 31 Jul 2028 |
| Enith2A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058Enicepatide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,600 est. | 7 Aug 2028 |
| MoonROSEA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerNCT07100106GDC-4198 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 285 est. | 31 Aug 2028 |
| A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseNCT07822334RO7830698 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 104 est. | 11 Oct 2028 |
| CEVOLUTIONCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaNCT07555938Cevostamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 380 est. | 31 Oct 2028 |
| optINAVOTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerNCT07368998Inavolisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 80 est. | 31 Oct 2028 |
| A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)NCT07425522RO7823653 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 93 est. | 17 Nov 2028 |
| Krascendo 2A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215Divarasib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 30 Nov 2028 |
| A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerNCT07405801Inavolisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 80 est. | 19 Dec 2028 |